Literature DB >> 1718886

Regulation of mediator release by human basophils: importance of the sequence and time of addition in the combined action of different agonists.

C A Dahinden1, S C Bischoff, T Brunner, M Krieger, S Takafuji, A L de Weck.   

Abstract

Biologically active molecules affecting basophil function can be divided into 4 groups according to their capacity to induce basophil degranulation and/or leukotriene generation: (1) full agonists such as anti-IgE or fMLP, which induce both histamine and leukotriene release; (2) partial agonists such as C5a, which induces degranulation only; (3) incomplete agonists such as neutrophil-activating peptide-1, platelet-activating factor or C3a, which induce mediator release only after cytokine preincubation, and (4) basophil response modifiers, such as interleukin-3, interleukin-5 and granulocyte/macrophage- colony-stimulating factor, which (a) enhance the releasability to all basophil agonists, (b) change the mediator profile, (c) enhance the rate of mediator release, (d) render basophils responsive to lower agonist concentrations and (e) render basophils responsive to incomplete agonists. We demonstrated that histamine release and de novo synthesis of lipid mediators are clearly separately regulated, and that combined actions of different molecules are of importance. In particular, the type(s), the time interval and the sequence of action of basophil-activating molecules are crucial for the final outcome of the basophil release reaction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718886     DOI: 10.1159/000235350

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  4 in total

Review 1.  [Basophil activation tests in the diagnosis of drug reactions].

Authors:  S M Erdmann; S Ventocilla; S Moll-Slodowy; I Sauer; H F Merk
Journal:  Hautarzt       Date:  2005-01       Impact factor: 0.751

Review 2.  Anaphylatoxins: their role in bacterial infection and inflammation.

Authors:  Pieter-Jan Haas; Jos van Strijp
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes.

Authors:  U Martin; D Bock; L Arseniev; M A Tornetta; R S Ames; W Bautsch; J Köhl; A Ganser; A Klos
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

Review 4.  The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.

Authors:  Yu Wang; Hui Zhang; You-Wen He
Journal:  Front Immunol       Date:  2019-07-19       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.